David B Miklos Selected Research

Lymphatic Irradiation

1/2019	Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
7/2017	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
11/2015	Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.
6/2014	Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.
6/2012	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
7/2009	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David B Miklos Research Topics

Disease

13	B-Cell Lymphoma (Lymphoma, B Cell) 10/2022 - 12/2017
12	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2019 - 01/2003
11	Neoplasms (Cancer) 10/2020 - 07/2009
8	Bronchiolitis Obliterans Syndrome 01/2018 - 04/2004
7	Leukemia 01/2019 - 01/2004
6	Lymphoma (Lymphomas) 10/2022 - 07/2009
4	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 06/2022 - 06/2012
4	Hematologic Neoplasms (Hematological Malignancy) 01/2019 - 09/2003
3	Residual Neoplasm 06/2022 - 09/2014
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 11/2012
3	Multiple Myeloma 01/2021 - 01/2021
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019 - 12/2017
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2016 - 12/2011
2	Infections 12/2021 - 04/2008
2	Body Weight (Weight, Body) 01/2020 - 12/2017
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2019 - 12/2017
2	Chronic Renal Insufficiency 03/2011 - 04/2008
1	Cytokine Release Syndrome 10/2022
1	COVID-19 01/2022
1	Plasma Cell Leukemia 12/2020
1	Inflammation (Inflammations) 10/2020
1	Disease Progression 01/2020
1	Sclerosis 01/2016
1	Sickle Cell Anemia (Hemoglobin S Disease) 07/2015
1	Hematologic Diseases (Blood Diseases) 05/2015
1	Inborn Genetic Diseases (Disease, Hereditary) 03/2015
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2014
1	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 06/2014
1	Pregnancy Complications 05/2014
1	Spontaneous Abortion (Miscarriage) 05/2014
1	Glucose Intolerance 05/2011
1	Insulin Resistance 05/2011
1	Immune System Diseases (Immune Disorders) 03/2011
1	Chronic Disease (Chronic Diseases) 03/2011
1	Renal Insufficiency (Renal Failure) 03/2011
1	Hodgkin Disease (Hodgkin's Disease) 08/2010
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 06/2010
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2010

Drug/Important Bio-Agent (IBA)

11	axicabtagene ciloleucelIBA 10/2022 - 12/2017
9	Chimeric Antigen ReceptorsIBA 10/2022 - 12/2017
8	AntibodiesIBA 01/2018 - 04/2005
6	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2019 - 07/2009
4	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2021 - 09/2003
4	Minor Histocompatibility AntigensIBA 04/2005 - 01/2003
3	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 10/2011
3	Rituximab (Mabthera)FDA Link 01/2016 - 04/2008
3	AntigensIBA 07/2015 - 04/2004
3	Biomarkers (Surrogate Marker)IBA 06/2013 - 02/2006
2	brexucabtagene autoleucelIBA 06/2022 - 01/2020
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021 - 10/2011
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2021 - 07/2009
2	Circulating Tumor DNAIBA 01/2021 - 01/2019
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2020 - 12/2016
2	SteroidsIBA 01/2018 - 06/2013
2	fludarabineIBA 12/2017 - 03/2015
2	H-Y antibodyIBA 07/2015 - 05/2014
2	AutoantibodiesIBA 05/2011 - 03/2011
2	CreatinineIBA 03/2011 - 04/2008
1	plerixafor FDA Link 01/2021
1	Lenalidomide (CC 5013)FDA Link 01/2021
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2021
1	VaccinesIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2019
1	AnthracyclinesIBA 01/2019
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2018
1	nilotinib FDA Link 01/2018
1	Interleukin-2 (IL2)IBA 12/2016
1	ibrutinibIBA 12/2016
1	Phosphotransferases (Kinase)IBA 12/2016
1	Busulfan (Busulfex)FDA Link 03/2015
1	Alemtuzumab (Campath)FDA Link 03/2015
1	Dihydrotachysterol (AT 10)IBA 09/2014
1	Immunoglobulins (Immunoglobulin)IBA 09/2014
1	H-Y AntigenIBA 02/2013
1	Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA 11/2012
1	Growth Factor ReceptorsIBA 10/2011
1	Immunoglobulin G (IgG)IBA 05/2011
1	Proteins (Proteins, Gene)FDA Link 03/2011
1	AngiotensinogenIBA 03/2011
1	Gemcitabine FDA Link 08/2010
1	Carmustine (FIVB)FDA Link 08/2010
1	Vinorelbine (Navelbine)FDA LinkGeneric 08/2010
1	Pharmaceutical PreparationsIBA 06/2010
1	EnzymesIBA 03/2010
1	ImmunosorbentsIBA 03/2010
1	HLA Antigens (Human Leukocyte Antigens)IBA 07/2009

Therapy/Procedure

15	Therapeutics 01/2022 - 02/2006
12	Cell Transplantation 01/2022 - 04/2008
8	Transplantation 03/2015 - 01/2003
7	Drug Therapy (Chemotherapy) 01/2022 - 04/2008
6	Lymphatic Irradiation 01/2019 - 07/2009
4	Stem Cell Transplantation 01/2022 - 01/2019
3	Aftercare (After-Treatment) 01/2021 - 12/2009
3	Hematopoietic Stem Cell Transplantation 01/2021 - 01/2004
2	Homologous Transplantation 01/2019 - 06/2014
2	Autologous Transplantation 06/2010 - 07/2009
1	Blood Component Removal (Apheresis) 01/2022
1	Hematopoietic Stem Cell Mobilization 01/2021
1	Erythrocyte Transfusion 07/2015
1	Cell- and Tissue-Based Therapy (Cell Therapy) 04/2008